Clinical Trial: Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer

U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07706179) titled 'Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer' on July 09.

Brief Summary: The goal of this clinical trial is to learn if alisertib in addition to usual care works to treat HR+/HER2+ breast cancer. The main questions it aims to answer are:

* Does alisertib stop the communication between HR and HER2?

* Are there genetic markers that predict how well someone's cancer will respond to alisertib?

Participants will receive alisertib in addition to their usual care.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: HR+/HER2+ Breast Cancer Metastatic Breast Cancer

Inte...